A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways-Reference-Cited by-同舟云学术

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

Published:2018-07-02 Issue:22 Volume:24 Page:5610-5621
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Romaniello Donatella,Mazzeo Luigi,Mancini Maicol,Marrocco Ilaria,Noronha Ashish,Kreitman Matthew,Srivastava Swati,Ghosh Soma,Lindzen Moshit,Salame Tomer Meir,Onn Amir,Bar Jair,Yarden Yosef

Funder

EC | European Research Council (ERC)

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib;Cell Reports Medicine;2024-08

2. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study;Journal for ImmunoTherapy of Cancer;2024-03

3. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma;Molecular Oncology;2024-01-18

4. In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies;iScience;2024-01

5. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status;Proceedings of the National Academy of Sciences;2023-11-16